Table 3 Microarray study characteristics
Study | Institution | Outcome | Microarray platform | Evaluated genes | Number of samplesa | Total time at risk, years | Median time at risk, years | Number deaths/recurrences |
|---|---|---|---|---|---|---|---|---|
Blenkiron, et al. [22] | Nottingham City Hospital (Nottingham, UK) | All-cause mortality | Illumina (San Diego, CA, USA) | PGC, FRS3, C6orf49, TRFP, BYSL, USP49, CCND3 | 128 | 1,198.0 | 11.1 | 45 |
Chin, et al. [23] | University of California at San Francisco | All-cause mortality | Affymetrix U133A (Santa Clara, CA, USA) | PGC, FRS3, C6orf49, TRFP, BYSL, CCND3 | 129 | 822.6 | 6.0 | 45 |
Miller, et al. [24] | Uppsala, Sweden | All-cause mortality | Affymetrix U133A | PGC, FRS3, C6orf49, BYSL, CCND3 | 234 | 1,927.5 | 10.2 | 54 |
Sørlie, et al. [25] | Stanford University (Stanford, CA, USA) | All-cause mortality | cDNA | BYSL, USP49, CCND3 | 76 | 227.6 | 2.5 | 30 |
Sotiriou, et al. [26] | John Radcliffe (Oxford, UK) | Disease recurrence | Affymetrix U133A | PGC, FRS3, TRFP, BYSL, CCND3 | 94 | 709.9 | 7.3 | 24b |
van de Vijver, et al. [27] | The Netherlands Cancer Institute (Amsterdam) | All-cause mortality | Agilent Technologies, Inc. (Santa Clara, CA, USA) | PGC, FRS3, C6orf49, BYSL, USP49, CCND3 | 295 | 2,319.8 | 7.2 | 79 |
Wang, et al. [28] | Erasmus (Rotterdam, The Netherlands) | Disease recurrence | Affymetrix U133A | PGC, C6orf49, FRS3, USP49, BYSL, CCND3 | 285 | 1,843.1 | 7.2 | 107b |
Total | Â | Â | Â | Â | 1,241 | 9,048.4 | 7.4 | 384 |